Placental Disease Overview

Principles

Definition

Placental disease is the academic and clinical domain dedicated to the study of pathological conditions impacting the development, structure, or function of the placenta. This field investigates the etiology, pathophysiology, diagnosis, treatment, and prevention of such conditions, characterized by its interdisciplinary integration of obstetrics, pathology, immunology, and molecular biology to understand and address adverse pregnancy outcomes and long-term health implications for both mother and offspring.

Ontological type

Pathophysiology

Diagnostic Approaches

Etiologic Factors

Key developments

Key Figures

Physiology and Endocrinology era

W. J. Hamilton [1] was affiliated with the University of Cambridge [3] and the University of Glasgow [4] during this era. His key contributions include advances in placental physiology and endocrine readouts exemplified by The Human Placenta [6] (1970), which helped establish transport, metabolism, and hormone transfer as measurable functions linked to fetal outcomes. J. D. Boyd [2] was affiliated with the University of Cambridge [3] and the University of Utah [5] in this era. His notable contribution includes co-authoring The Human Placenta [6] (1970) with Hamilton, providing a framework for in vitro metabolism and perfusion studies that clarified placental endocrine readouts and their implications for surveillance of hypertensive and postmaturity complications.

Immune-Vascular Regulation era

Scott W. Walsh[1], associated with Johns Hopkins University[3] and Washington University in St. Louis[4], helped define the immune-vascular regulation focus of placental disease in this era. His key contributions include identifying an imbalance in placental prostacyclin and thromboxane production[7], showing that TNFα concentrations and mRNA expression are increased in preeclamptic placentas[8], and highlighting lipid peroxidation in pregnancy[9], advancing the understanding of vascular maladaptation and its links to hypertensive pregnancy syndromes. Napoleone Ferrara[2], whose work with Harvard University[5] and the University of California, San Francisco[6] situates this era's explorations of placental angiogenesis, anchors the era's focus on angiogenic regulation. His Placenta growth factor[10] paper (1994) demonstrates potentiation of vascular endothelial growth factor bioactivity and high affinity binding to Flt-1, not to Flk-1/KDR, underscoring the role of placental angiogenic signaling in regulating placental perfusion during immune-vascular regulation.

Angiogenic Imbalance and Biomarkers era

S. Ananth Karumanchi [1] is a leading figure whose work is associated with Harvard University [3] and The University of Texas Southwestern Medical Center [4]. His key contributions include the 2003 paper Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia [6], the 2004 paper First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia [7], and the 2010 paper First Trimester Vitamin D, Vitamin D Binding Protein, and Subsequent Preeclampsia [8]. Raymond W. Redline [2] is a prominent figure whose affiliations include Harvard University [3] and Washington University in St. Louis [5], with papers such as Amniotic Infection Syndrome: Nosology and Reproducibility of Placental Reaction Patterns [9], Maternal Vascular Underperfusion: Nosology and Reproducibility of Placental Reaction Patterns [10], and Placental diagnostic criteria and clinical correlation – a workshop report [11]. This nosology and workshop-driven criteria [11] provided foundational groundwork for integrating placental pathology with subsequent biomarker-guided risk stratification in hypertensive pregnancy disorders.